Roivant Sciences director Vivek Ramaswamy reports multi-day share sales

Rhea-AI Filing Summary

Roivant Sciences Ltd. director and more-than-10% owner Vivek Ramaswamy reported multiple open-market sales of the company’s common shares. On 11/13/2025 he sold 287,283 shares at a weighted average price of $20.81, on 11/14/2025 he sold 1,027,670 shares at a weighted average of $20.33, and on 11/17/2025 he sold 539,650 shares at a weighted average of $20.51. The prices reflect multiple individual trades within stated ranges for each day. After these transactions, he beneficially owned 33,653,756 common shares directly and 13,357,857 common shares indirectly through his spouse.

Insights

Equity Ownership and Governance Analyst

Large insider share sale by a major holder, but substantial ownership stake remains significant.

The filing reports that **Vivek Ramaswamy**, a director and more than 10% owner of **Roivant Sciences Ltd.**, sold an aggregate of 1,854,603 common shares across three transactions on 11/13/2025, 11/14/2025, and 11/17/2025. The weighted average sale prices were around $20.81, $20.33, and $20.51, with specific trading ranges disclosed in the footnotes. After these sales, he still directly holds 33,653,756 common shares, plus 13,357,857 shares held indirectly through a spousal position.

This matters because such a holder combines roles as director and large shareholder, so changes in stake can influence perceptions of alignment between leadership and other owners. The filing shows only open-market sales of non-derivative common shares and no reported activity in options or other derivatives. The detailed price ranges and the note that indirect holdings are spousal clarify the structure of his remaining economic interest.

Key items to watch are any future Form 4 filings that show additional reductions or changes in this ownership profile, as well as whether direct versus indirect holdings shift over time. The dated transactions through 11/17/2025 provide a reference point for tracking subsequent ownership trends and governance influence.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ramaswamy Vivek

(Last) (First) (Middle)

C/O STEVE ROBERTS

700 PENNSYLVANIA AVE., SE STE. 440

(Street)

WASHINGTON DC 20003

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Roivant Sciences Ltd. [ ROIV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
11/13/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	11/13/2025		S		287,283	D	$20.81(1)	35,221,076	D
Common Shares	11/14/2025		S		1,027,670	D	$20.33(2)	34,193,406	D
Common Shares	11/17/2025		S		539,650	D	$20.51(3)	33,653,756	D
Common Shares								13,357,857(4)	I	Spousal

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.54 to $21.08, inclusive. The reporting person undertakes to provide to Roivant Sciences Ltd., any security holder of Roivant Sciences Ltd., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (2), and (3) to this Form 4.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $21.11, inclusive.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.20 to $20.72, inclusive.

4. Represents the quantity of shares held indirectly only.

	/s/ Stephen Roberts, as Attorney-in-Fact for Vivek Ramaswamy	11/17/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Roivant Sciences (ROIV) disclose in this Form 4?

The filing shows that director and more-than-10% owner Vivek Ramaswamy sold Roivant Sciences common shares in three open-market transactions on 11/13/2025, 11/14/2025, and 11/17/2025.

How many Roivant Sciences (ROIV) shares did Vivek Ramaswamy sell and at what prices?

He sold 287,283 shares at a weighted average price of $20.81 on 11/13/2025, 1,027,670 shares at $20.33 on 11/14/2025, and 539,650 shares at $20.51 on 11/17/2025.

What price ranges applied to the Roivant Sciences (ROIV) insider sales?

For 11/13/2025, trades ranged from $20.54 to $21.08. For 11/14/2025, trades ranged from $20.00 to $21.11. For 11/17/2025, trades ranged from $20.20 to $20.72.

How many Roivant Sciences (ROIV) shares does Vivek Ramaswamy own after these transactions?

After the reported sales, he beneficially owned 33,653,756 Roivant Sciences common shares directly and 13,357,857 common shares indirectly through his spouse.

Are the reported Roivant Sciences (ROIV) sale prices single trades or averages?

The reported prices of $20.81, $20.33, and $20.51 are weighted average prices, with each day’s sales executed in multiple transactions within specified price ranges.

Does this Roivant Sciences (ROIV) Form 4 involve any derivative securities?

The table for derivative securities is included, but no derivative transactions are reported; only common share sales appear in the non-derivative section.